secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001564590-22-006688
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind reports 2021 revenue $75.4M, +16%; Afrezza Q4 record $11.3M; net loss widens
--------------------------------------------------------------------------------

- Total revenues 2021: $75.4M (+16% vs 2020); Afrezza net revenue $39.2M (+21% YoY)
- Q4 Afrezza net revenue $11.3M (+13% vs Q4 2020); collaborations revenue $1.2M
- Cash and investments $260.7M at Dec 31, 2021 vs $67.2M a year ago; includes $230M convertible note and ~$100M sale-leaseback
- Full-year net loss $80.9M ($0.32/sh) vs $57.2M ($0.26/sh) in 2020; non-GAAP loss $61.7M ($0.25/sh)
- Tyvaso DPI PDUFA deadline extended to May 2022; clofazimine Phase 1 trial commenced in 1Q 2022

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459022006688/0001564590-22-006688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459022006688/mnkd-8k_20220224.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-006688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer